70 Participants Needed

DPCP for Skin Diseases

NY
HX
Overseen ByHui Xu, MD, PhD
Age: 18+
Sex: Any
Trial Phase: Phase < 1
Sponsor: University of Alabama at Birmingham
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The overall goal of this study is to determine novel mechanisms for ultraviolet light (UV)-induced suppression of the immune system in human subjects and to improve understanding of UV-induced skin carcinogenesis.

Who Is on the Research Team?

CE

Craig Elmets, MD

Principal Investigator

Univ. of Alabama at Birmingham

TD

Tyler Downing, MD

Principal Investigator

University of Alabama at Birmingham

Are You a Good Fit for This Trial?

This trial is for individuals aged 18-35 who understand the study's requirements and risks, and can consent to participate. It excludes those with certain skin pigment disorders, a history of skin cancer or photosensitivity, high sun exposure risk including tanning parlors, darker skin types (Fitzpatrick IV-VI), immune system conditions or drug use affecting immunity, and women who are pregnant or lactating.

Inclusion Criteria

Patient able to sign a consent form
I understand what participating in the study involves and its risks.

Exclusion Criteria

I have had an organ transplant, have an immune disorder, or am taking immunosuppressive medication.
A woman who is lactating, pregnant, or planning to become pregnant
A known history of photosensitivity disorders
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are stratified into Control, Non-UVB, or UVB groups and receive treatments with DPCP and/or UVB exposure

5-10 weeks
3-10 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including measurement of skin bifold thickness

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Diphenylcyclopropenone (DPCP)
Trial Overview The study aims to explore how ultraviolet light (UV) suppresses the immune system which may affect skin cancer development. Participants will be treated with Diphenylcyclopropenone (DPCP), a substance used in immunotherapy for dermatological purposes.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Active Control
Group I: Group 3 (UVB & Biopsy 30 participants)Experimental Treatment1 Intervention
Group II: Group 2 (Positive Control, 20 participants)Experimental Treatment1 Intervention
Group III: Group 1 (Negative Control, 20 participants)Active Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials
1,677
Recruited
2,458,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security